Similar items over time

Drug - Marplan (Isocarboxazid), Roche, circa 1965 Object Reg. No: SH 850264

Marplan is the trade name for the drug isocarboxazid, one of the hydrazine class of antidepressants, manufactured by Roche, circa 1965. It was stocked in a psychiatric hospital pharmacy in Victoria, Australia. Isocarboxazid is a monoamine oxidase inhibitor (MAOI) and was prescribed for its antidepressant and anxiolytic properties. Due to its strength, significant side-effects and ability to react with some foods, Marplan was considered for patients for whom other antidepressant treatments had failed to have any effect, as a drug of last resort.
Drug Marplan (isocarboxazid) is in tablet-form contained in a small, flat, clear plastic box (sealed) inside which is blue and white cardboard packet, labelled MARPLAN. Originally held 200 but that has been crossed out and 100 substituted in handwriting. Contains lead pieces.
Acquisition Information:
Donation from Office of Psychiatric Services
Discipline: History
Dimensions: 3.50 cm (Height), 1.00 cm (Width), 5.00 cm (Length)

More information

Tagged with: psychiatric hospitals, pharmaceuticals, hospitals, mental health, mental health institutions, psychiatric services, medicines, psychiatric institutions, medicinals drugs, drugs, making history - psych services
Themes this item is part of: Medicine in Society Collection, Psychiatric Services Collection, Public Life & Institutions Collection
Primary Classification: MEDICINE & HEALTH
Secondary Classification: Mental Health - Pharmacy
Tertiary Classification: pharmaceuticals
Inscriptions: Text: [200] Tablets/ 'MARPLAN'/ Trade Mark/ 100 (printed on front and back of packet)
Manufacturer: Roche, Australia, Circa 1965
Place Used: Victoria, Australia, Circa 1965
References: Martindale. The extra pharmacopoeia. London. Pharmaceutical Press. 1972.

Add your comment

  • Museum Victoria does not provide valuations, for more information please visit the valuation infosheet
  • Please note that Museum Victoria staff will not normally respond to comments posted on our website.
Yes No